explore -WSS

explore

author：focus 2025-08-23 18:38:17 - browse：23

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

WSS

WHO recommends second malaria vaccine

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

The stability of $0 premiums in Medicare Advantage

Congress likely to miss an opportunity to fix drug shortages issue

Who gets to use the title 'doctor'?

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

focus

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Congress extends some pandemic preparedness programs

The cancer drug shortage isn’t new — and neither are the solutions

Why police arrested suspected Gilgo Beach killer away from his house

At least 13 dead in Texas as scorching temps continue

Will an HIV vaccine ever be a reality?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Cancer drug shortages should be causing more outrage

Why police arrested suspected Gilgo Beach killer away from his house

knowledge

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Europe sees delivery challenges ahead on Alzheimer's therapies

Who gets to use the title 'doctor'?

With Roe v Wade overturned, abortion providers work to adapt

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

What we owe ALS patients — and why one company fell short

focus

focus

focus

focus